Daniel J. George, MD

Director, GU Oncology, Duke Cancer Institute

Duke University School of Medicine

Dr Daniel George is a tenured Associate Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He an internationally recognized clinical researcher and thought leader in GU malignancies, with over 100 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr George is principal investigator of the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of the PCF 5000, an international, multi-sponsor supported registry in advanced prostate cancer.

Nationally, Dr George has served on the ASCO scientific committee from 2010-2012 and as the program chair of the GU committee in 2012. He currently serves on two grant committees for AACR. He is the scientific leader for kidney cancer in the Alliance Cooperative Group since 2011 and serves on the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research, Clinical Advances in Hematology and Oncology, and Prostate Cancer and Prostatic Diseases.

Selecting and Sequencing Therapies for Advanced Prostate Cancer

New Directions in the Management of Advanced Prostate Cancer

Michael R. Harrison, MD

Assistant Professor of Medicine

Duke University School of Medicine

Patrick F. Fogarty, MD

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Perelman School of Medicine, University of Pennsylvania

Manish A. Shah, MD

Director, Gastrointestinal Oncology

Weill Cornell Medical College

Dr. Manish A. Shah completed his undergraduate education at Johns Hopkins University in 1991, going on to receive his Medical Degree from Harvard Medical School/MIT Health Sciences and Technology program in 1996, graduating Magna Cum Laude. He completed his Internal Medicine Residency training at Duke University Medical Center in 1999, and his Fellowship at Memorial Sloan-Kettering Cancer Center in 2001, where he served as Chief Oncology Fellow. Dr. Shah was recruited from Memorial Sloan-Kettering Cancer Center in order to serve as Director of the Gastrointestinal Oncology Program within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care at Weill Cornell Medical College/ NewYork-Presbyterian Hospital. Dr. Shah is the recipient of several awards including the American Society of Clinical Oncology’s Young Investigator and Career Development Awards, as well as the Journal for Surgical Oncology’s Donald L. Morton Award. Most recently, Dr. Shah was the recipient of the Bartlett Family Associate Professor for Gastrointestinal Oncology award. Dr. Shah is a distinguished peer-review funded investigator and has led several Phase I, II and III clinical trials in GI malignancies. His areas of translational research interests focus on improving the understanding of upper GI cancers, hereditary GI malignancies, genomic evaluations of malignancy, and the effects of the external environment on the genetic causes of malignancy.

In addition to his research pursuits, Dr. Shah is involved in several extramural professional responsibilities. Dr. Shah is a member of the American Society of Clinical Oncology (ASCO) and the American Association for Clinical Research (AACR). He has authored several books, including Dx/Rx: Upper Gastrointestinal Malignancies: Cancers of the Stomach and Esophagus, as well as 100 Questions and Answers about Stomach Cancer. Dr. Shah is the Editor for The Management of Complex Cases in Gastrointestinal Oncology Case Series for the Journal of Gastrointestinal Oncology and the Series Editor for the Dx/RX: Oncology Series published by Jones and Bartlett Publishers. In addition, Dr. Shah serves on the Editorial Board of the Journal of Clinical Oncology, and as a reviewer for several high-impact journals, including Journal of the American Medical Association, PLOS One, and Lancet Oncology. Additionally, Dr. Shah serves as Chair of the Scientific Advisory Board for the DeGregorio Family Foundation for Stomach and Esophageal Cancer Education and Research, and Vice Chair of the National Cancer Institute’s Gastroesophageal Task Force.

Personalizing the Management of Advanced Gastric Cancer

Julie M. Vose, MD, MBA

Neumann M. and Mildred E. Harris Professor

University of Nebraska Medical Center

Julie M. Vose, MD is the Neumann M. and Mildred E. Harris Professor and Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center in Omaha, Nebraska. Dr Vose received her medical degree, completed her residency in Internal Medicine, served as Chief Resident, and completed a Fellowship in Hematology/Oncology at the University of Nebraska Medical Center. Dr Vose also completed a sabbatical at Stanford University. She also completed an MBA in Health Administration through the University of Colorado Business School.

Dr Vose has focused her career on translational research for improvement in the therapy of non-Hodgkin’s lymphoma (NHL) and Hodgkin lymphoma (HL) by developing a focused translational research program evaluating novel therapies such as radiolabeled monoclonal antibodies, idiotype vaccine therapies, pathway directed agents and stem cell transplantation. Dr Vose has been recognized for her NHL research on a national and international level through research awards and invited lectureships worldwide. In addition, her funding record and publications in NHL therapy and transplantation research have added substantially to the research and knowledge base for the therapy of lymphoma. She is currently the Co-Chair for the National Cancer Institute Lymphoma Sub-Committee, a member of the FDA Oncologic Drug Advisory Committee, and 2014-15 President elect for the American Society of Clinical Oncology (ASCO).

New Directions in the Management of Mantle Cell Lymphoma

James O. Armitage, MD

The Joe Shapiro Professor of Medicine

University of Nebraska Medical Center

Dr. James O. Armitage, a graduate of the University of Nebraska Medical Center, completed his internship and residency in internal medicine at Nebraska, a fellowship in hematology oncology at the University of Iowa and a brief stint in private practice in Omaha. He developed and directed the Bone Marrow Transplant program at the University of Iowa and later at the University of Nebraska. At Nebraska he served as Vice-Chair of Internal Medicine, Chief of the Section of Oncology and Hematology, Chair of the Department of Internal Medicine, and Dean of the College of Medicine. He currently is The Joe Shapiro Professor of Medicine at the University of Nebraska Medical Center. Dr. Armitage is board certified in internal medicine, medical oncology, and hematology, and a Fellow of both the American and Royal College of Physicians and of the American Association for the Advancement of Sciences. He has served on many national/international oncology committees including the United States National Cancer Advisory Board and the French National Cancer Advisory Board. He is past president of both the American Society of Clinical Oncology and the American Society of Blood and Marrow Transplantation. He has served on the Scientific Committee of the International Congress on Anti-Cancer Treatment in Paris, France, the International Symposium on Hodgkin Lymphoma in Cologne, Germany and the International Conference on Malignant Lymphoma in Lugano, Switzerland.

He has numerous honors including the Claude Jacquillat Award for achievement in Clinical Oncology from Paris, the San Salvatore Foundation Research Award from Lugano, Switzerland, the Richard and Hinda Rosenthal Foundation Award from the American Association of Cancer Research, the Heath Memorial Award from the University of Texas MD Anderson Cancer Center, the Robert A. Kyle Award from the Mayo Clinic, and election to the Association of American Physicians. Dr. Armitage has published more than 500 papers, written 110 chapters and is co-editor of 27 books. He and his wife, Nancy, have four children and ten grandchildren.

New Directions in the Management of Mantle Cell Lymphoma

Andrew Zelenetz, MD, PhD

Vice Chair, Department of Medicine

Professor of Medicine, Weill-Cornell Medical College

Andrew D. Zelenetz, MD, PhD is the Vice Chair, Medical Informatics in the Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York. Prior to that, he had held the position of Chief, Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994-January, 2013. He is also Professor of Medicine at Weill Medical College of Cornell University.
He has helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies he is evaluating the benefits of novel combinations of agents. In another area of research he is working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology and Clinical Cancer Research.
Dr. Zelenetz received his BA from Harvard College, his PhD from Harvard University’s Graduate School of Arts and Sciences, Division of Medical Sciences and his MD from Harvard Medical School. Both his internship and residency in medicine were completed at Stanford University Medical Center as well as a clinical fellowship and research fellowship in oncology.
Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He participates in various committees: he is Vice Chairperson of the Cancer and Leukemia Group B Lymphoma Core Committee, Chair of the NCCN Non-Hodgkin’s Lymphoma Panel, Board Member of the Leukemia and Lymphoma Society and member of the Lymphoma Research Foundation Scientific Advisory Board. He has been the recipient of the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times and has received the Rodger Winn Award from the National Comprehensive Cancer Network in 2012.

Managing Diffuse Large B-cell Lymphoma (DLBCL): A Case-based Approach to Treatment Selection

Evaluating New & Emerging Treatment Options for Non-Hodgkin Lymphoma (NHL)

Andre Goy, MD, MS

Chairman and Director and Chief of Lymphoma

John Theurer Cancer Center, at Hackensack University Medical Center

Andre Goy, M.D., M.S., is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin’s disease, non-Hodgkin’s lymphoma, and HIV-associated lymphoma. As chief of John Theurer Cancer Center’s Division of Lymphoma, he leads New Jersey’s largest program for research, treatment and management of lymphoma. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris and The Pasteur Institute.
Dr. Goy was instrumental in developing the John Theurer Cancer Center’s Tissue Bank, where samples of cells, tissue, and other anatomical structures are stored and analyzed for research purposes. The Tumor Bank has received more than 1,600 patient consents since it launched.
Dr. Goy is widely-known for his work showing the first evidence of activity of bortezomib in mantle cell lymphoma and then as co-principal investigator on the PINNACLE trial, which led to the Food & Drug Administration’s approval of VELCADE® (bortezomib) for relapsed / refractory mantle cell lymphoma patients in 2006. He also took part in the original pilot study for RITUXAN® (rituximab), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders.
Dr. Goy’s research centers on developing novel targeted therapies for lymphoma and developing biomarkers for lymphoma. He has been invited to speak and teach around the world, and his research has been published extensively. He is a journal reviewer for eight medical publications that include: Blood, Clinical Cancer Research and the Journal of Clinical Oncology.

Managing Diffuse Large B-cell Lymphoma (DLBCL): A Case-based Approach to Treatment Selection

Evaluating New & Emerging Treatment Options for Non-Hodgkin Lymphoma (NHL)

Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits